A series of updates have emerged from
Thermo Fisher Scientific: the company recently reduced its profit forecast for 2025 due to tariffs and research funding cuts. Despite this, it continues to be seen as a strong growth and investment opportunity, with
Waverton Investment Management Ltd adding 52,324 shares of the company to their portfolio. The company has recently beat
EPS quarterly earnings forecasts, and completed a
US$3 billion buyback with rising Q1 earnings. In a massive feat, Thermo Fisher committed a
$2B investment in U.S operations aimed at transforming American life sciences. Various products and innovations like an advanced sustainable Centrifuge line and the 5L DynaDrive single-use Bioreactor have been launched.
Prospects of an impending acquisition of Solventum’s Purification and Filtration Business are in the air and an
increase in quarterly dividend was announced. However, there has been a negative sentiment due to Shares hitting a< b>52-week low amid market shifts. Nonetheless, the company shows immense potential to upscale in the biotech sector, making it a significant player to watch.
Thermo Fisher Scientific TMO News Analytics from Thu, 07 Nov 2024 08:00:00 GMT to Thu, 24 Apr 2025 20:16:02 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor 4
